{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:06:05Z","timestamp":1790888765722,"version":"4.1.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"Importance<\/jats:title>High out-of-pocket costs and improper use of maintenance inhalers contribute to poor outcomes among patients with chronic obstructive pulmonary disease (COPD). There is limited evidence for how addressing these barriers could improve adherence and affect COPD exacerbations, spending, or racial disparities in these outcomes.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the effect of a national program to reduce beneficiary cost sharing for COPD maintenance inhalers and provide medication management services that included education on proper technique for inhaler use.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This randomized clinical trial included individuals with COPD. All individuals were enrolled in Medicare Advantage. Data were collected from January 2019 to December 2021, and data were analyzed from January 2023 to May 2024.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services. The random assignment of the invitation was used to estimate the effects of the invitation and program enrollment, overall and by race.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Inhaler adherence measured as proportion of days covered (PDC), moderate-to-severe exacerbations, short-acting inhaler fills, total spending, and as an exploratory outcome, out-of-pocket spending.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 19\u202f113 included patients, 55.2% were female; 9.5% were Black, 81.1% were White, and 9.4% were another or unknown race; and the median (IQR) age was 74 (69-80) years. Program enrollment was higher in the invited group (29.4%) than the control group (5.1%). The PDC for maintenance inhalers was higher in the invited group than the control group (32.0% vs 28.4%; adjusted invitation effect, 3.8 percentage points; 95% CI, 3.1-4.5); the adjusted effect of the program (the local average treatment effect) was 15.5 percentage points (95% CI, 12.8-18.1), a 55% relative increase in adherence. Mean (SD) out-of-pocket spending for prescriptions was lower in the invited group ($619.5 [$863.1]) than the control group ($675.0 [$887.3]; adjusted invitation effect, \u2212$49.5; 95% CI, \u221268.9 to \u221230.0; adjusted program effect, \u2212$203.0; 95% CI, \u2212282.8 to \u2212123.2), but there was no statistically significant difference in exacerbations, short-acting inhaler fills, or total spending. Among Black individuals, the adjusted invitation effect on maintenance inhaler PDC was 5.5 percentage points (95% CI, 3.3-7.7), and the adjusted program effect was 19.5 percentage points (95% CI, 12.4-26.7). Among White individuals, the adjusted invitation effect was 3.7 percentage points (95% CI, 2.9-4.4), and the adjusted program effect was 15.1 percentage points (95% CI, 12.1-18.1). The difference between the invitation effects by race was not statistically significant (1.8 percentage points; 95% CI, \u22120.5 to 4.1; P<\/jats:italic>\u2009=\u2009.13).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Individuals in Medicare Advantage who received an invitation to enroll in a program that reduced cost sharing for maintenance inhalers and provided medication management services had higher inhaler adherence compared with the control group. The difference in the program\u2019s effect on inhaler adherence between Black and White individuals was substantial but not statistically significant.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT05497999<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2024.3499","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T15:38:05Z","timestamp":1722267485000},"page":"1186","source":"Crossref","is-referenced-by-count":5,"title":["Reduced Cost Sharing and Medication Management Services for COPD"],"prefix":"10.1001","volume":"184","author":[{"given":"Sumit D.","family":"Agarwal","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Metzler","sequence":"additional","affiliation":[{"name":"Humana Inc, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chernew","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Thomas","sequence":"additional","affiliation":[{"name":"Humana Inc, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie G.","family":"Press","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Boudreau","sequence":"additional","affiliation":[{"name":"Humana Inc, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Powers","sequence":"additional","affiliation":[{"name":"Humana Inc, Louisville, Kentucky"},{"name":"Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"McWilliams","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"ioi240045r2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/COPD.S3036","article-title":"Medication adherence issues in patients treated for COPD.","volume":"3","author":"Restrepo","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"ioi240045r3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4187\/respcare.05905","article-title":"Adherence in asthma and COPD: new strategies for an old problem.","volume":"63","author":"George","year":"2018","journal-title":"Respir Care"},{"issue":"3","key":"ioi240045r4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1378\/chest.09-3031","article-title":"Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease.","volume":"138","author":"Castaldi","year":"2010","journal-title":"Chest"},{"issue":"6","key":"ioi240045r5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11606-010-1624-2","article-title":"Misuse of respiratory inhalers in hospitalized patients with asthma or COPD.","volume":"26","author":"Press","year":"2011","journal-title":"J Gen Intern Med"},{"issue":"4","key":"ioi240045r6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1164\/rccm.201810-1909PP","article-title":"Chronic obstructive pulmonary disease in America\u2019s Black population.","volume":"200","author":"Ejike","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"ioi240045r9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2105\/AJPH.2007.124446","article-title":"Alternatives to the randomized controlled trial.","volume":"98","author":"West","year":"2008","journal-title":"Am J Public Health"},{"key":"ioi240045r10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-publhealth-071521-025758","article-title":"Using rapid randomized trials to improve health care systems.","volume":"44","author":"Horwitz","year":"2023","journal-title":"Annu Rev Public Health"},{"issue":"10","key":"ioi240045r11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s11606-012-2090-9","article-title":"Teaching the use of respiratory inhalers to hospitalized patients with asthma or COPD: a randomized trial.","volume":"27","author":"Press","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"6","key":"ioi240045r12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1513\/AnnalsATS.201509-603OC","article-title":"Effectiveness of interventions to teach metered-dose and diskus inhaler techniques. a randomized trial.","volume":"13","author":"Press","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"ioi240045r13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2147\/COPD.S302241","article-title":"Development and validation of a healthcare utilization-based algorithm to identify acute exacerbations of chronic obstructive pulmonary disease.","volume":"16","author":"Mapel","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"434","key":"ioi240045r14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/01621459.1996.10476902","article-title":"Identification of causal effects using instrumental variables.","volume":"91","author":"Angrist","year":"1996","journal-title":"J Am Stat Assoc"},{"issue":"51","key":"ioi240045r16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2311556120","article-title":"Instrumental variables methods reconcile intention-to-screen effects across pragmatic cancer screening trials.","volume":"120","author":"Angrist","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ioi240045r17","doi-asserted-by":"publisher","first-page":"c2073","DOI":"10.1136\/bmj.c2073","article-title":"An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials.","volume":"340","author":"Sussman","year":"2010","journal-title":"BMJ"},{"issue":"11","key":"ioi240045r18","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1164\/rccm.201810-1865ST","article-title":"Improving the affordability of prescription medications for people with chronic respiratory disease. an official American Thoracic Society policy statement.","volume":"198","author":"Patel","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"ioi240045r19","article-title":"Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).","author":"Janjua","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"ioi240045r20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1513\/AnnalsATS.202008-1082RL","article-title":"Trends in Medicare Part D inhaler spending: 2012-2018.","volume":"18","author":"Feldman","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"ioi240045r21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamainternmed.2016.9386","article-title":"Medicare Part D plans\u2019 coverage and cost-sharing for acute rescue and preventive inhalers for chronic obstructive pulmonary disease.","volume":"177","author":"Tseng","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"2","key":"ioi240045r22","doi-asserted-by":"publisher","first-page":"w195","DOI":"10.1377\/hlthaff.26.2.w195","article-title":"Value-Based Insurance Design.","volume":"26","author":"Chernew","year":"2007","journal-title":"Health Aff (Millwood)"},{"issue":"7","key":"ioi240045r23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1377\/hlthaff.2012.0902","article-title":"Value-Based Insurance Design: quality improvement but no cost savings.","volume":"32","author":"Lee","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"20","key":"ioi240045r24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.123.064188","article-title":"Eliminating medication copayments for low-income older adults at high cardiovascular risk: a randomized controlled trial.","volume":"147","author":"Campbell","year":"2023","journal-title":"Circulation"},{"issue":"8","key":"ioi240045r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.31259","article-title":"Utilization and spending with preventive drug lists for asthma medications in high-deductible health plans.","volume":"6","author":"Sinaiko","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"22","key":"ioi240045r26","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","article-title":"Full coverage for preventive medications after myocardial infarction.","volume":"365","author":"Choudhry","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"ioi240045r27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/jamainternmed.2019.4472","article-title":"Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN Meds randomized clinical trial.","volume":"180","author":"Persaud","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"5","key":"ioi240045r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.1127","article-title":"Effect of free medicine distribution on health care costs in Canada over 3 years: a secondary analysis of the CLEAN Meds randomized clinical trial.","volume":"4","author":"Persaud","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"2","key":"ioi240045r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5309","article-title":"Acute diabetes complications after transition to a value-based medication benefit.","volume":"5","author":"Wharam","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"25","key":"ioi240045r30","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJM198112173052504","article-title":"Some interim results from a controlled trial of cost sharing in health insurance.","volume":"305","author":"Newhouse","year":"1981","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi240045r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.1440","article-title":"Rethinking health insurance design.","volume":"2","author":"Baicker","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"3","key":"ioi240045r32","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/qje\/qjx013","article-title":"What does a deductible do? the impact of cost-sharing on health care prices, quantities, and spending dynamics.","volume":"132","author":"Brot-Goldberg","year":"2017","journal-title":"Q J Econ"},{"issue":"12","key":"ioi240045r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4804","article-title":"Cost-sharing reform for chronic disease treatments as a strategy to improve health care equity and value in the US.","volume":"3","author":"Essien","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"5","key":"ioi240045r34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1377\/hlthaff.2013.0654","article-title":"Eliminating medication copayments reduces disparities in cardiovascular care.","volume":"33","author":"Choudhry","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"ioi240045r35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1377\/hlthaff.2012.1061","article-title":"What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs.","volume":"32","author":"Hibbard","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"ioi240045r36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1377\/hlthaff.2020.01699","article-title":"Fewer pharmacies in Black and Hispanic\/Latino neighborhoods compared with White or diverse neighborhoods, 2007-15.","volume":"40","author":"Guadamuz","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"23","key":"ioi240045r37","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMp1610821","article-title":"Cost containment and the tale of care coordination.","volume":"375","author":"McWilliams","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"ioi240045r38","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0037-2021","article-title":"Measuring adherence to therapy in airways disease.","volume":"17","author":"Holmes","year":"2021","journal-title":"Breathe (Sheff)"},{"key":"ioi240045r40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1472-6963-7-175","article-title":"Impact of prescription size on statin adherence and cholesterol levels.","volume":"7","author":"Batal","year":"2007","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"ioi240045r41","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s11606-011-1805-7","article-title":"The comparative effectiveness of mail order pharmacy use vs. local pharmacy use on LDL-C control in new statin users.","volume":"26","author":"Schmittdiel","year":"2011","journal-title":"J Gen Intern Med"},{"key":"ioi240045r8","volume-title":"Evaluation of Phase II of the Medicare Advantage Value-Based Insurance Design Model Test","author":"Eibner","year":"2023"},{"key":"ioi240045r15","first-page":"203","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020"},{"key":"ioi240045r1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2023 Report. Accessed July 31, 2023. https:\/\/goldcopd.org\/wp-content\/uploads\/2023\/03\/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf"},{"key":"ioi240045r7","unstructured":"US Centers for Medicare & Medicaid Services. Medicare Advantage Value-Based Insurance Design model. Accessed October 30, 2023. https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/vbid"},{"key":"ioi240045r39","unstructured":"DuBard? CA, Shrank? WH, Cavanaugh? S, Mostashari? F. Why the star ratings medication adherence measures must go. Accessed April 8, 2024. https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20240103.310349\/full\/"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2821705\/jamainternal_agarwal_2024_oi_240045_1727970866.12694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T15:02:33Z","timestamp":1728313353000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2821705"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2024.3499","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}